366.44USD-2.06%Mkt Cap: 197.77B $P/E: 25.501d ago
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthriti…
Industry Peers
Drug Manufacturers - Generalvs Drug Manufacturers - General
P/E
Pricier
P/B
Pricier
Div Yield
Lower
1M Perf
Lower
$1.07TUSDP/E 42.6
$624.26BUSDP/E 30.0
$461.26BUSDP/E 128.0
$307.10BUSDP/E 21.1
$313.12BUSDP/E 35.7
$278.99BUSDP/E 22.3
$287.55BUSDP/E 28.7
$272.43BUSDP/E 22.1
$268.95BUSDP/E 28.0
$206.99BUSDP/E 11.7
$160.92BUSDP/E 17.6
$135.19BUSDP/E 18.1
$115.79BUSDP/E 15.9
$96.93BUSDP/E 18.8
$86.34BUSDP/E 14.0
$54.65BUSD
$30.78BUSDP/E 22.4
MRV
Marvell Technology, Inc.$25.88BUSDP/E 9.8
$11.38BUSDP/E 22.9
$10.80BUSDP/E 18.8
$10.72BUSDP/E 18.6
$6.71BUSDP/E 14.9
$3.56BUSDP/E 14.6
$2.96BUSDP/E 18.1
$56.76MUSD
$40.13MUSD
ELXR
Elixxer Ltd.$9.51MUSD
FLXN
Horizon Flexible Income ETF—P/E 27.3
ROSE
DocMorris AG—
CELG-RI
Bristol-Myers Squibb Company Ce—
Indicators:|
Key Statistics
Company
Market Cap197.77B $
Enterprise Value240.72B $
Revenue (TTM)37.22B $
Gross Profit24.71B $
Net Income (TTM)7.71B $
Revenue/Share69.12 USD
Last Price366.44 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees31.5K
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - General
ISINUS0311621009
Valuation
P/E (Trailing)25.50
P/E (Forward)15.43
PEG1.96
EV/EBITDA14.23
EV/Revenue6.47
P/S5.25
P/B21.27
EPS (TTM)14.39
EPS (Forward)23.46
52W Range
269.7780% of range391.29
52W High391.29 USD
52W Low269.77 USD
Profitability
Gross Margin67.25%
Oper. Margin33.80%
EBITDA Margin45.45%
Profit Margin20.98%
ROE89.06%
ROA8.51%
Growth
Revenue Growth5.80%
Earnings Growth4.40%
Cash Flow & Leverage
Operating CF9.96B $
CapEx (TTM)1.86B $
FCF Margin19.98%
FCF Yield3.76%
Net Debt45.29B $
Net Debt/EBITDA2.68
Balance Sheet
Debt/Equity6.31
Current Ratio1.26
Quick Ratio0.85
Book Value/Sh17.03 USD
Cash/Share22.30 USD
Dividends
Fwd Div Rate10.08 USD
Trail. Div Rate9.660 USD
Div. Yield2.78%
5Y Avg Yield3.07%
Payout Ratio67.22%
Ex-Div DateMay 15, 2026
Pay DateJun 5, 2026
Splits
Last Split2:1
Split DateNov 22, 1999
Analyst Consensus
Rating2.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)352.77 USD
Upside (mean)-3.7%
Target Range200.00 USD – 427.00 USD
$200.00-3.7% to mean$427.00
# Analysts30
Ownership
Shares Out.539.71M
Float538.23M
Insiders0.22%
Institutions85.25%
Short Interest
Short Ratio4.4d
Short % Float2.26%
Short % Out.2.26%
Shares Short12.20M
Short (prev mo.)12.29M
Technical
SMA 50340.45 (+7.6%)
SMA 200334.02 (+9.7%)
Beta0.42
S&P 52W Chg20.05%
Avg Vol (30d)2.51M
Avg Vol (10d)3.51M
Technical Indicators
RSI (14)62.5
MACD6.8407
MACD Signal4.7614
MACD Hist.+2.0793
BB Upper371.27 USD
BB Middle352.17 USD
BB Lower333.07 USD
BB Width10.85%
ATR (14)8.955 USD
Vol Ratio (20d)0.89x